Literature DB >> 18473850

Advanced glycation end products and insulin resistance.

Hiroyuki Unoki1, Sho-ichi Yamagishi.   

Abstract

Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of advanced glycation end products (AGEs) in vivo. There is a growing body of evidence that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being involved in the pathogenesis of diabetic vascular complications. Further, recently, engagement of their receptor, RAGE with AGEs is shown to activate its down-stream signaling and evoke oxidative stress and inflammation in diabetes. Since oxidative stress generation and inflammation are closely associated with insulin resistance as well, it is conceivable that the AGEs-RAGE system could play a role in the pathogenesis of insulin resistance and subsequently the development of diabetes. In this paper, we review the role of the AGEs-RAGE system in insulin resistance, especially focusing on its effects on the insulin-signaling pathways in skeletal muscles and adipocytes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473850     DOI: 10.2174/138161208784139747

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  49 in total

1.  Processed Meat, but Not Unprocessed Red Meat, Is Inversely Associated with Leukocyte Telomere Length in the Strong Heart Family Study.

Authors:  Amanda M Fretts; Barbara V Howard; David S Siscovick; Lyle G Best; Shirley Aa Beresford; Mihriye Mete; Sigal Eilat-Adar; Nona Sotoodehnia; Jinying Zhao
Journal:  J Nutr       Date:  2016-08-24       Impact factor: 4.798

Review 2.  An overview of in vitro and in vivo glycation of albumin: a potential disease marker in diabetes mellitus.

Authors:  Km Neelofar; Jamal Ahmad
Journal:  Glycoconj J       Date:  2017-08-15       Impact factor: 2.916

3.  Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice.

Authors:  Myoung Jin Son; Miki Minakawa; Yutaka Miura; Kazumi Yagasaki
Journal:  Eur J Nutr       Date:  2012-12-13       Impact factor: 5.614

4.  Dietary consumption of advanced glycation end products and pancreatic cancer in the prospective NIH-AARP Diet and Health Study.

Authors:  Li Jiao; Rachael Stolzenberg-Solomon; Thea Palmer Zimmerman; Zhigang Duan; Liang Chen; Lisa Kahle; Adam Risch; Amy F Subar; Amanda J Cross; Albert Hollenbeck; Helen Vlassara; Gary Striker; Rashmi Sinha
Journal:  Am J Clin Nutr       Date:  2014-11-19       Impact factor: 7.045

5.  TCF7L2 polymorphism and cognitive test performance in cardiovascular disease.

Authors:  Therese Anne Keary; John Gunstad; Andreana Benitez; Mary Beth Spitznagel; Jeanne McCaffery; John E McGeary; Athena Poppas; Robert H Paul; Lawrence H Sweet; Ronald A Cohen
Journal:  Psychogeriatrics       Date:  2012-06       Impact factor: 2.440

6.  Cardiovascular dementia - a different perspective.

Authors:  Udhaya Kumari; Klaus Heese
Journal:  Open Biochem J       Date:  2010-03-26

Review 7.  Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine.

Authors:  Jean Robert Rapin; Nicolas Wiernsperger
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

8.  Increased expression and local accumulation of the prion protein, Alzheimer Aβ peptides, superoxide dismutase 1, and nitric oxide synthases 1 & 2 in muscle in a rabbit model of diabetes.

Authors:  Claudine L Bitel; Yicheng Feng; Nizar Souayah; Peter H Frederikse
Journal:  BMC Physiol       Date:  2010-09-06

Review 9.  Insulin resistance: an emerging link in Alzheimer's disease.

Authors:  Bikash Medhi; Mrinmoy Chakrabarty
Journal:  Neurol Sci       Date:  2013-05-14       Impact factor: 3.307

10.  Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks.

Authors:  Mohamed Rowisha; Manal El-Batch; Thanaa El Shikh; Salwa El Melegy; Hany Aly
Journal:  Pediatr Res       Date:  2016-03-18       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.